Recap Of Thursday’s Biotech Catalysts – End of The Day Summary
Cyclerion Therapeutics (NASDAQ:CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive…
Gilead’s Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
Gilead Sciences Inc (NASDAQ:GILD) announced results reinforcing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a highly efficacious treatment option for HIV, including individuals with…
Aethlon Medical Highlights Publication Of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding Of Seven COVID-19 Variants
Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
AIM ImmunoTech Reports Positive Pilot Study Data From Expanded Access Program Evaluating Ampligen For The Treatment Of Long COVID-19
AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune
Atossa Therapeutics Announces Dosing Completed In Part C of Atossa’s Phase 1/2a Study Of AT-H201 In Healthy Volunteers
Atossa Therapeutics, Inc. (NASDAQ:ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a
Keytruda, Gardasil Boost Merck’s Q2 Revenues, Tightens Annual Guidance
Merck & Co Inc’s (NYSE: MRK) Q2 sales reached $14.60 billion, +28% Y/Y, beating the consensus of $13.87 billion. Excluding the…
Allergan To End Around 3,000 Opioid Lawsuits With Over $2B In Settlement: Report
AbbVie Inc’s (NYSE:ABBV) Allergan unit has agreed to pay more than $2 billion to resolve over 3,000 lawsuits filed…
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…